![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Ultragenyx to Pay $6M Settlement Over Kickback Allegations for Crysvita
Ultragenyx to Pay $6M Settlement Over Kickback Allegations for Crysvita
Ultragenyx Pharmaceutical has agreed to pay $6 million to resolve allegations that it caused the submission of false claims to Medicare and Medicaid, according to the Department of Justice (DOJ).
DOJ said in a statement that Ultragenyx was paying for free genetic tests and paying a separate fee to receive test result information, all to induce prescriptions of its drug Crysvita.
The drug was approved in 2018 to treat X-linked hypophosphatemia (XLH), a rare form of rickets characterized by low levels of phosphate in the blood. The disease can lead to muscle cramps, weak bones and, in many instances require a genetic test for a definitive diagnosis.
To read the whole story, click here to subscribe.
Related Topics
Upcoming Events
-
11Jul
-
18Jul
-
21Oct